The U.S. Food and Drug Administration (FDA) has cleared Lantheus Medical Imaging's Definity ultrasound contrast agent for pediatric patients.
The FDA's decision was based on data from three pediatric trials conducted with Definity, Lantheus said; the three studies included a total of 189 patients. All reported adverse events across all trials were "mild, brief, and reversible without intervention," according to the firm.
